Skip to content
HowShorted

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2023

In 2023, ARROWHEAD PHARMACEUTICALS, INC.'s disclosed short interest ran from 4.35% of shares outstanding on 13 Jan 2023 to 6.97% on 29 Dec 2023, a change of +2.62 percentage points. The year's high was 7.35% on 15 Nov 2023 and its low 4.27% on 28 Feb 2023, averaging 5.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.16 days on 31 Aug 2023. Full history: ARROWHEAD PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ARROWHEAD PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
4.35% (13 Jan 2023)
End of year
6.97% (29 Dec 2023)
Change
+2.62 pp
High
7.35% (15 Nov 2023)
Low
4.27% (28 Feb 2023)
Average
5.39%
Highest days to cover
8.16 (31 Aug 2023)
SEC filings marked
7

Every report in 2023

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.35%3.14
31 Jan 20234.32%5.64
15 Feb 20234.38%5.3110-Q filed
28 Feb 20234.27%6.19
15 Mar 20235.08%3.63
31 Mar 20234.57%4.18
14 Apr 20234.51%4.86
28 Apr 20234.53%3.99
15 May 20234.90%4.7310-Q filed, results (8-K)
31 May 20234.62%5.26
15 Jun 20234.67%6.75
30 Jun 20234.41%4.42
14 Jul 20234.83%5.56
31 Jul 20235.20%6.92
15 Aug 20235.65%5.9410-Q filed, results (8-K)
31 Aug 20235.91%8.16
15 Sep 20235.69%5.74
29 Sep 20235.59%7.62
13 Oct 20236.65%6.02
31 Oct 20236.69%7.48
15 Nov 20237.35%7.24
30 Nov 20237.11%5.8010-K filed, results (8-K)
15 Dec 20237.22%4.00
29 Dec 20236.97%7.89

See also: ARROWHEAD PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.